OncoSec Announces Closing of First Tranche of $15 Million At Market Investment from Alpha Holdings, Inc.

Published: Oct 09, 2018

 

SAN DIEGO and PENNINGTON, N.J., Oct. 9, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the closing of the first $8 million tranche of its $15 million investment from Alpha Holdings, Inc. (KOSDAQ: 117670). This value-focused, fundamental strategic investment is centered on the clinical development of OncoSec's lead immunotherapy product candidate, TAVO (tavokinogene telseplasmid). TAVO enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with powerful immune-stimulating functions. 

Alpha Holdings is a leading Korean technology company engaged in the design, development, service and manufacture of system semiconductors, as well as the development of biotechnologies and thermal compound materials. Since 2002, Alpha Holdings has successfully carried out many projects as a major partner of Samsung Advanced Foundry Eco-system (SAFE) of Samsung Electronics. Alpha Holdings, a listed company in the KOSDAQ Market, was founded in 2002 and is headquartered in Seongnam, South Korea.

Under the terms of the agreement, Alpha Holdings has committed to purchase a total of $15 million worth of shares of common stock from OncoSec in two tranches at $1.50 per share. The two tranches are each subject to a six-month holding requirement from date of funding. As stated above, Alpha has funded the first tranche of $8 million. The closing of the second tranche is subject to the satisfaction of certain closing conditions. Further details of the transaction can be found in the Form 8-K filed by the Company describing the agreement.

About Alpha Holdings, Inc. 
Alpha Holdings, Inc. is a top-ranked Korean company engaged in the design-development service and manufacture of system semiconductors. Since 2002, Alpha Holdings has successfully carried out many projects as a major partner of SAFE (Samsung Advanced Foundry Eco-system) of Samsung Electronics. The company, formerly known as Alpha Chips Corp. changed its name to Alpha Holdings, Inc. in August 2016 and has expanded its business area into biotechnologies and thermal compound materials. Alpha Holdings has invested more than 20 million USD in innovative biotechnology companies. Alpha Holdings, a listed company in the KOSDAQ Market, was founded in 2002 and is headquartered in Seongnam, South Korea. For more information, please visit www.alpha-holdings.co.kr.

About OncoSec Immunotherapies
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer.  OncoSec's lead immunotherapy platform – TAVO (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders.  Results from recently completed clinical studies of TAVO have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach. In addition to TAVO, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its ImmunoPulse® platform. For more information, please visit www.oncosec.com.

CONTACT 
Investor Relations:
Stern Investor Relations 
Will O'Connor 
Phone: (212) 362-1200
will@sternir.com

Media Relations:
David Schemelia / Jason Rando 
Tiberend Strategic Advisors, Inc. 
Phone: 212-827-0020  
dschemelia@tiberend.com  
jrando@tiberend.com

OncoSec Medical Incorporated logo (PRNewsfoto/OncoSec Medical Incorporated)

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/oncosec-announces-closing-of-first-tranche-of-15-million-at-market-investment-from-alpha-holdings-inc-300727682.html

SOURCE OncoSec Medical Incorporated

 
 
Company Codes: NASDAQ-SMALL:ONCS, Korea:117670
 

Back to news